EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Harnessing Nanohybridized Niclosamide for Precision Mpox Therapeutics

N Sanoj Rejinold iD, Geun-Woo Jin iD, Jin-Ho Choy iD

Advanced Healthcare Materials · 2025

DOI: 10.1002/adhm.202404818 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von N Sanoj Rejinold und 2 weiteren Autor:innen. Beteiligte Einrichtung: Intelligent Nanohybrid Materials Laboratory (INML), Department of Chemistry, College of Science and Technology, Dankook University, Cheonan, 31116, R…. Hauptthemen laut MEDLINE: Niclosamide, Antiviral Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Niclosamide, initially developed as an anthelmintic, has recently emerged as a potential antiviral, showing efficacy against diverse viral threats, including Mpox. As the global health landscape faces recurrent Mpox outbreaks, repurposing niclosamide through advanced material strategies offers promising therapeutic avenues. This article explores the antiviral mechanisms of niclosamide, focusing on how innovative nano‐hybrid formulations enhance its bioavailability and pharmacological performance. By leveraging nanohybridization, niclosamide's limitations—such as poor solubility and bioavailability—are addressed, enabling targeted delivery and sustained release. Early preclinical studies reveal that niclosamide disrupts Mpox replication and entry processes, suggesting its utility as a therapeutic option against poxvirus infections. Looking forward, further in vitro, animal models, and clinical investigations are essential to optimize its application and dosing for Mpox. With continued development in advanced materials, nanohybrid niclosamide could become a critical tool in managing Mpox and related viral threats, offering an accessible, cost‐effective option for outbreak preparedness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NiclosamideAntiviral AgentsHumansAnimalsDrug RepositioningMpox, Monkeypox

Stichwörter der Autor:innen

Mpox antiviral therapybioavailability enhancementnanohybrid formulationsniclosamide repurposingpoxvirus therapeutic strategies

Substanzen

NiclosamideAntiviral Agents

Autor:innen und Institutionen

  • Intelligent Nanohybrid Materials Laboratory (INML), Department of Chemistry, College of Science and Technology, Dankook University, Cheonan, 31116, Republic of Korea.
  • R&D Center, Hyundai Bioscience Co. LTD, Seoul, 03759, Republic of Korea.
  • Division of Natural Sciences, The National Academy of Sciences, Seoul, 06579, Republic of Korea.
  • Tokyo Tech World Research Hub Initiative (WRHI), Institute of Innovative Research, Institute of Science Tokyo, Yokohama, 226-8503, Japan.

ORCID-Profile: N Sanoj Rejinold, Geun-Woo Jin, Jin-Ho Choy

Förderung

  • National Academy of Sciences

Zitieren

APA

Rejinold, N. S., Jin, G. W., & Choy, J. H. (2025). Harnessing Nanohybridized Niclosamide for Precision Mpox Therapeutics. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202404818

Vancouver

Rejinold NS, Jin GW, Choy JH. Harnessing Nanohybridized Niclosamide for Precision Mpox Therapeutics. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202404818

BibTeX
@article{Rejinold2025,
  author = {Rejinold, N Sanoj and Jin, Geun-Woo and Choy, Jin-Ho},
  title = {Harnessing Nanohybridized Niclosamide for Precision Mpox Therapeutics},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  doi = {10.1002/adhm.202404818}
}
Kostenlos starten →